Navigation Links
Kaiser Permanente Study Finds Boys More Likely to Receive HPV Vaccine When Their Mothers Receive Preventive Care
Date:7/18/2013

PASADENA, Calif., July 18, 2013 /PRNewswire/ -- Boys are more likely to receive the quadrivalent human papillomavirus vaccine if their mothers receive flu shots or Pap screenings, according to a Kaiser Permanente study published in the American Journal of Public Health. The study examined the electronic health records of more than 250,000 boys aged 9 to 17 years enrolled in the Kaiser Permanente Southern California health plan and found that a total of 4,055 boys – or 1.6 percent of the study participants – initiated the HPV4 vaccine between October 2009 and December 2010. Researchers found that the HPV4 vaccination rate was 16 percent higher in boys whose mothers had received a flu shot within the previous year than in boys whose mothers did not. In addition, the vaccination rate was 13 percent higher in boys whose mothers had a Pap screening in the last three years than boys whose mothers did not have a Pap test.

The study also found that boys whose mothers had a history of genital warts were 47 percent more likely to receive the HPV4 vaccine, although the researchers note that this association did not reach statistical significance. In addition, HPV4 vaccine uptake was found to be higher among boys who were Hispanic, resided in neighborhoods with lower levels of income and educational attainment, and enrolled in a Medicaid program.

"Our study findings suggest that a mother's receipt of preventive services may have an impact on their son's HPV4 vaccination," said Rulin Hechter, MD, PhD, study lead author and researcher with the Kaiser Permanente Southern California Department of Research & Evaluation. "These mothers might be more familiar with preventive measures for HPV infection, influencing their decision to have their children vaccinated."

According to the Centers for Disease Control and Prevention, HPV is a common virus that is easily spread by skin-to-skin contact and is considered to be the main cause of cervical cancer in women, with about 12,000 new cases each year in the United States. The CDC considers the HPV vaccine a safe and effective way to protect females and males against some of the most common types of HPV and the health problems the virus can cause.

In October 2009, the CDC's Advisory Committee on Immunization Practices issued a "permissive use" recommendation for the HPV4 vaccine, which meant that the vaccine was recommended for boys aged 9 to 26 to reduce the likelihood of acquiring genital warts, but it was not included in the routine childhood vaccine schedule for boys. In these instances, parents often played a deciding role as to whether their sons would receive the vaccine. However in late 2010, the CDC approved the new vaccine indication for anal cancer. In 2011, the ACIP issued a "routine use" recommendation of HPV4 vaccination in males aged 11 to 12 years. Under a routine use recommendation, physicians are more likely to promote the vaccine. The researchers are collecting additional data following the introduction of indication for anal cancer and the routine use recommendation to further understand the impact of the changes in recommendation on uptake of this vaccine among boys.

"Given that vaccination offers an opportunity to achieve community immunity and reduce transmission of HPV, understanding a mother's health-seeking behaviors may help health care professionals develop strategies for increasing vaccination rates among adolescent boys," Dr. Hechter said.

Kaiser Permanente can conduct transformational health research in part because it has the largest private patient-centered electronic health system in the world. The organization's electronic health record system, Kaiser Permanente HealthConnect®, securely connects 9.1 million patients to 1,700 physicians in 611 medical offices and 37 hospitals. It also connects Kaiser Permanente's research scientists to one of the most extensive collections of longitudinal medical data available, facilitating studies and important medical discoveries that shape the future of health and care delivery for patients and the medical community.

Additional authors on the study include Chun Chao, PhD, Lina S. Sy, MPH, Bradley K. Ackerson, MD, Jeff M. Slezak, MS, Margo A. Sidell, Sc.D., and Steven J. Jacobsen, MD, PhD,with the Kaiser Permanente Southern California Department of Research & Evaluation.

About the Kaiser Permanente Southern California Department of Research & Evaluation
The Department of Research & Evaluation (R & E) conducts high-quality, innovative research into disease etiology, prevention, treatment and care delivery. Investigators conduct epidemiology, health sciences, and behavioral research as well as clinical trials. Areas of interest include diabetes and obesity, cancer, HIV/AIDS, cardiovascular disease, aging and cognition, pregnancy outcomes, women's and children's health, quality and safety, and pharmacoepidemiology. Located in Pasadena, Calif., the department focuses on translating research to practice quickly to benefit the health and lives of Kaiser Permanente Southern California members and the general population. Visit: www.kp.org/research.

About Kaiser Permanente
Kaiser Permanente is committed to helping shape the future of health care. We are recognized as one of America's leading health care providers and not-for-profit health plans. Founded in 1945, our mission is to provide high-quality, affordable health care services and to improve the health of our members and the communities we serve. We currently serve more than 9.1 million members in nine states and the District of Columbia. Care for members and patients is focused on their total health and guided by their personal physicians, specialists and team of caregivers. Our expert and caring medical teams are empowered and supported by industry-leading technology advances and tools for health promotion, disease prevention, state-of-the-art care delivery and world-class chronic disease management. Kaiser Permanente is dedicated to care innovations, clinical research, health education and the support of community health. For more information, go to: kp.org/newscenter.

For more information, contact:
Vincent Staupe, vstaupe@golinharris.com, 415.318.4386
Sandra Hernandez-Millett, sandra.d.hernandez-millett@kp.org, 626.405.5384


'/>"/>
SOURCE Kaiser Permanente
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine
2. Kaiser Permanente Study Finds Varied Reasons Why Patients Do Not Fill their Initial Statin Prescriptions
3. Nearly 30 Percent of Women Fail to Pick Up New Prescriptions for Osteoporosis, Kaiser Permanente Study Finds
4. Doug Bonacum of Kaiser Permanente Named to List of 50 Experts Leading the Field of Patient Safety
5. Kaiser Permanente Receives Award for Excellence in Medication Safety
6. Kaiser Permanente Members Share Stories of Survival for Februarys Heart Health Month
7. Jack Cochran, MD, Executive Director of The Permanente Federation at Kaiser Permanente, named to National Quality Forum Board
8. Kaiser Permanente Joins Rock Health to Support Digital Innovation in Health Care
9. Kaiser Permanente Appoints Alexandra Morehouse as Vice President of Advertising and Brand Management
10. Four Million People Choose Connectivity and Convenience with Kaiser Permanentes Personal Health Record
11. My Health Manager Users More Likely to Remain Kaiser Permanente Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... JERUSALEM , Sept. 5, 2017 Oramed Pharmaceuticals ... www.oramed.com ), a clinical-stage pharmaceutical company focused on the ... it has successfully concluded its meeting with the U.S. ... novel oral insulin formulation. ... that the regulatory pathway for submission of ORMD-0801, would ...
(Date:8/29/2017)... 29, 2017 ivWatch, LLC, the leading provider of continuous ... it has been awarded an Innovative Technology contract from Vizient, Inc., ... ... aid in the early detection of peripheral IV infiltration and extravasation ... The Innovative Technology contract was awarded ...
Breaking Medicine Technology:
(Date:9/22/2017)... ... , ... "Success Files," a short- and long-form documentary style ... disease estimated to affect the lives of more than 5 million Americans living ... leading voice in the fight for cure and research into the disease, its ...
(Date:9/22/2017)... ... 2017 , ... Egg freezing and embryo freezing are both ... slight statistical advantage for live births, frozen eggs offer many advantages, depending on ... medical treatment or who are concerned about the decline of their fertility as ...
(Date:9/21/2017)... ... 2017 , ... SABRE is raising awareness about personal safety with a Chicago ... November. , The Chicago, Illinois, based self-defense brand has been waiting for an opportunity ... of taking their personal safety into their own hands. , The ads focus on ...
(Date:9/21/2017)... (PRWEB) , ... September 21, 2017 , ... Bill Howe ... to its customers, and give back to the community. For over 37 years, they ... most successful companies serving plumbing in San Diego. They were chosen as ...
(Date:9/21/2017)... ... September 21, 2017 , ... Japanese Zen artist couple, ... Revolution” on 6th, 7th and 8th October at Miranda Kuo Gallery on Lower East ... pieces, such as Zen Kodo mat. Wanderlust , one of the largest US ...
Breaking Medicine News(10 mins):